Quantcast

Latest CytRx Corporation Stories

2014-10-30 08:33:52

LOS ANGELES, Oct. 30, 2014 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced an upcoming presentation highlighting its novel technology and its lead drug candidate, aldoxorubicin. The presentation, titled, "Drug Conjugates Bind Covalently to Albumin: A New Approach," will be given by Sant P. Chawla, M.D., F.R.A.C.P., Director of the Sarcoma Oncology Center and principal investigator of the...

2014-10-29 08:31:56

LOS ANGELES, Oct. 29, 2014 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that a paper, titled "Therapeutic Efficacy of Aldoxorubicin in an Intracranial Xenograft Mouse Model of Human Glioblastoma," has been published online in Neoplasia (Volume 16, Issue 10). The paper amplifies previously reported positive preclinical data that demonstrated that aldoxorubicin significantly increased survival...

2014-10-20 08:30:08

LOS ANGELES, Oct. 20, 2014 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that a paper, titled "A Phase 1b/2 Study of Aldoxorubicin in Patients With Soft Tissue Sarcoma," has been published online in Cancer, the prestigious, peer-reviewed journal of the American Cancer Society. The paper discusses results from CytRx's completed Phase 1b/2 clinical trial where 25 patients were enrolled, including...

2014-10-17 08:25:10

Trial Has Not Yet Reached Necessary Number of Survival Events to Report on Overall Survival Due to Longer than Expected Survival of Study Patients LOS ANGELES, Oct. 17, 2014 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that data regarding the Company's Phase 2b global clinical trial of aldoxorubicin for the treatment of first-line soft tissue sarcoma (STS) will be presented in a moderated...

2014-10-16 08:30:19

LOS ANGELES, Oct. 16, 2014 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its Board of Directors has appointed Steven A. Kriegsman, President, Chief Executive Officer and a Director of the Company, as Chairman of the Board, effective October 15, 2014. He replaces Max E. Link, Ph.D. whose unexpected passing was announced on October 7, 2014. "I am honored to assume the additional...

2014-10-13 08:26:19

Expected to Yield First Clinical Candidate in 2015 LOS ANGELES, Oct. 13, 2014 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has commenced operations at its new discovery laboratory, located in Freiburg, Germany. The new laboratory will conduct discovery and translational research to create drug candidates that utilize novel linker technologies that couple chemotherapeutic...

2014-10-09 08:26:38

LOS ANGELES, Oct. 9, 2014 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the initiation of enrollment in an open-label Phase 1b clinical trial designed to investigate the preliminary safety and activity of aldoxorubicin plus gemcitabine in subjects with metastatic solid tumors. Aldoxorubicin is CytRx's modified version of the widely-used chemotherapeutic agent, doxorubicin. The Phase 1b...

2014-10-07 16:27:01

LOS ANGELES, Oct. 7, 2014 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced Max E. Link, Ph.D., Chairman of the Board of Directors, passed away unexpectedly at the age of 74. "We are deeply saddened by the loss of our dear friend and colleague, and our thoughts are with his family during this difficult time," said Steven A. Kriegsman, CytRx President and Chief Executive Officer. "Max was a...

2014-09-30 08:30:56

Completion of Enrollment Expected in 2015; Progression-Free Survival Data Expected in mid-2016 LOS ANGELES, Sept. 30, 2014 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the initiation of a global Phase 2b clinical trial evaluating aldoxorubicin compared to topotecan in subjects with extensive-stage small cell lung cancer (SCLC) who have relapsed or were refractory to prior chemotherapy....

2014-09-29 08:29:30

Follows CytRx's Strategy to Develop a Global Oncology Franchise in Numerous Orphan Indications LOS ANGELES, Sept. 29, 2014 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted multiple Orphan Drug Designations for the Company's lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme (GBM), small cell lung...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related